Immunocore (IMCR) Stock Price, News & Analysis

Company Overview

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma. Beyond this, Immunocore’s pipeline includes multiple additional ImmTAC candidates in various stages of clinical evaluation across solid tumor indications such as colorectal, lung and other metastatic cancers. The firm also pursues collaborations with major biopharmaceutical partners to expand the reach and application of its TCR technology, notably with Genentech and Fosun Pharma.

Headquartered in Oxford, England, with research and development facilities in Philadelphia, Pennsylvania, Immunocore leverages a global infrastructure to support its clinical trials and manufacturing efforts. Founded in 2008, the company is led by Chief Executive Officer Dr. Bahija Jallal, under whose direction Immunocore has advanced its first‐in‐class therapies from discovery through late‐stage clinical development. With a commitment to innovation in immune‐based medicine, Immunocore continues to explore new targets and indications that may benefit from the specificity and potency of its TCR‐based platform.

Key Stats

• Today's Range: $34.70 to $35.56
• 50-Day Range: $27.79 to $35.54
• 52-Week Range: $27.56 to $40.71
• Volume: 224,406 shs
• Average Volume: 468,892 shs
• Market Capitalization: $1.79 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.71
• Consensus Rating: Hold

Immunocore Stock Analysis - MarketRank™

Immunocore scored higher than 54% of companies evaluated by MarketBeat, and ranked 402nd out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Immunocore has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Immunocore has a consensus price target of $56.71, representing about 61.1% upside from its current price of $35.21.

Amount of Analyst Coverage

Immunocore has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 983.33%

Earnings Growth

Earnings for Immunocore are expected to grow by 983.33% in the coming year, from $0.06 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunocore is -63.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunocore is -63.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunocore has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.66% of the float of Immunocore has been sold short.

Short Interest Ratio / Days to Cover

Immunocore has a short interest ratio ("days to cover") of 12.51, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunocore has recently decreased by 0.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunocore does not currently pay a dividend.

Dividend Growth

Immunocore does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Immunocore this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for IMCR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Immunocore to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immunocore insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.10% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/24/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCR
• CIK: 1671927
• Web: www.immunocore.com
• Phone: 44-12-3543-8600
• Fax: N/A
• Employees: 320
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immunocore: $56.71
• High Price Target: $100.00
• Low Price Target: $33.00
• Potential Upside/Downside: +61.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 585.48
• P/E Growth: N/A
• Net Income: -$35.51 million
• Net Margins: -6.68%
• Pretax Margin: -2.89%
• Return on Equity: -7.07%
• Return on Assets: -2.55%

Debt

• Debt-to-Equity Ratio: 1.00
• Current Ratio: 4.18
• Quick Ratio: 4.15

Sales & Book Value

• Annual Sales: $400.02 million
• Price / Sales: 4.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.52 per share
• Price / Book: 4.67

Miscellaneous

• Outstanding Shares: 50,870,000
• Free Float: 45,729,000
• Market Cap: $1.79 billion
• Optionable: Optionable
• Beta: 0.73